相似文献
1
Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease.
Vaccines (Basel). 2022 Jun 9;10(6):920. doi: 10.3390/vaccines10060920.
2
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
Lancet. 2022 Mar 26;399(10331):1254-1264. doi: 10.1016/S0140-6736(22)00011-3. Epub 2022 Mar 15.
3
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Lancet Infect Dis. 2023 Sep;23(9):1020-1030. doi: 10.1016/S1473-3099(23)00199-8. Epub 2023 May 19.
4
Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
Cureus. 2022 Jul 27;14(7):e27323. doi: 10.7759/cureus.27323. eCollection 2022 Jul.
5
Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
Iran J Immunol. 2022 Sep;19(3):321-329. doi: 10.22034/iji.2022.94298.2300.
6
Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
Heliyon. 2023 Nov 7;9(11):e21877. doi: 10.1016/j.heliyon.2023.e21877. eCollection 2023 Nov.
7
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
BMC Public Health. 2022 Aug 20;22(1):1584. doi: 10.1186/s12889-022-14016-9.
8
Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
Vaccine. 2023 Mar 17;41(12):1925-1933. doi: 10.1016/j.vaccine.2023.01.032. Epub 2023 Jan 23.
9
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
Geroscience. 2021 Oct;43(5):2321-2331. doi: 10.1007/s11357-021-00471-6. Epub 2021 Oct 11.
10
Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
Front Med (Lausanne). 2023 Jul 17;10:1176168. doi: 10.3389/fmed.2023.1176168. eCollection 2023.
引用本文的文献
1
Self-Reported Adverse Events Following COVID-19 Vaccination Among Medical Sciences Students After a Symptomatology Training Program: A Cross-Sectional Study.
Health Sci Rep. 2025 Mar 2;8(3):e70492. doi: 10.1002/hsr2.70492. eCollection 2025 Mar.
2
COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis.
Microorganisms. 2025 Jan 10;13(1):135. doi: 10.3390/microorganisms13010135.
3
Evaluation of BBIBP-CorV Sinopharm COVID-19 vaccine effectiveness in Sri Lanka: a test-negative case control study.
BMJ Open. 2024 Nov 28;14(11):e090341. doi: 10.1136/bmjopen-2024-090341.
4
Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
Front Immunol. 2024 Nov 13;15:1448408. doi: 10.3389/fimmu.2024.1448408. eCollection 2024.
5
How well do different COVID-19 vaccines protect against different viral variants? A systematic review and meta-analysis.
Trans R Soc Trop Med Hyg. 2025 Jan 3;119(1):1-12. doi: 10.1093/trstmh/trae082.
6
Is there a Possible Association between Multiple Myeloma Relapse and Coronavirus Disease 2019 Vaccination? A Case Report.
J Res Pharm Pract. 2024 Sep 26;13(1):27-32. doi: 10.4103/jrpp.jrpp_21_24. eCollection 2024 Jan-Mar.
7
Comparing the immunogenicity of COVID-19 infection and vaccination in pregnant women as measured by anti-S IgG.
BMC Infect Dis. 2024 Sep 9;24(1):935. doi: 10.1186/s12879-024-09853-5.
8
Ocular Implications of COVID-19 Infection and Vaccine-Related Adverse Events.
J Pers Med. 2024 Jul 23;14(8):780. doi: 10.3390/jpm14080780.
9
The Equal Neutralizing Effectiveness of BNT162b2, ChAdOx1 nCoV-19, and Sputnik V Vaccines in the Palestinian Population.
Vaccines (Basel). 2024 May 3;12(5):493. doi: 10.3390/vaccines12050493.
10
Exploring the relationship between SARS-CoV-2 variants, illness severity at presentation, in-hospital mortality and COVID-19 vaccination in a low middle-income country: A retrospective cross-sectional study.
Health Sci Rep. 2023 Dec 1;6(12):e1703. doi: 10.1002/hsr2.1703. eCollection 2023 Dec.
本文引用的文献
1
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021.
Travel Med Infect Dis. 2023 May-Jun;53:102565. doi: 10.1016/j.tmaid.2023.102565. Epub 2023 Mar 16.
2
Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern.
Nat Commun. 2022 Apr 4;13(1):1788. doi: 10.1038/s41467-022-29477-0.
3
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
Lancet. 2022 Mar 26;399(10331):1254-1264. doi: 10.1016/S0140-6736(22)00011-3. Epub 2022 Mar 15.
4
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
J Infect Dis. 2022 Oct 17;226(8):1372-1381. doi: 10.1093/infdis/jiac092.
5
Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE.
J Travel Med. 2022 Sep 17;29(6). doi: 10.1093/jtm/taac036.
6
Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2041945. doi: 10.1080/21645515.2022.2041945. Epub 2022 Feb 24.
7
Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
Vaccine. 2022 Mar 18;40(13):2003-2010. doi: 10.1016/j.vaccine.2022.02.039. Epub 2022 Feb 19.
8
Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021.
China CDC Wkly. 2022 Jan 28;4(4):57-65. doi: 10.46234/ccdcw2022.009.
9
Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
Front Med. 2022 Feb;16(1):93-101. doi: 10.1007/s11684-021-0914-x. Epub 2022 Feb 3.
10
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
Mol Immunol. 2022 Mar;143:94-99. doi: 10.1016/j.molimm.2022.01.009. Epub 2022 Jan 17.
Zotero 插件